An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening

被引:111
作者
Culot, Maxime [1 ]
Lundquist, Stefan [2 ]
Vanuxeem, Dorothee [1 ]
Nion, Stephane [3 ]
Landry, Christophe [1 ]
Delplace, Yannick [3 ]
Dehouck, Marie-Pierre [1 ]
Berezowski, Vincent [1 ]
Fenart, Laurence [1 ]
Cecchelli, Romeo [1 ]
机构
[1] Univ Artois, Lab Physiopathol Barriere Hemato Encephal, EA 2465, IMPRT,IFR 114,Fac Jean Perrin, F-62307 Lens, France
[2] AstraZeneca R&D Soedertaelje, Dept Drug Metab & Pharmacokinet, S-15185 Soedertaelje, Sweden
[3] Fac Jean Perrin, CELLIAL Technol, Lens, France
关键词
blood-brain barrier; in vitro model; high throughput screening; drug discovery; toxicity; endothelial cells;
D O I
10.1016/j.tiv.2007.12.016
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
There is a growing interest to use in vitro BBB cell assays in early safety assessment of compounds. By modifying a well-validated coculture model of brain capillary endothelial and glial cells, developed by Dehouck et al. [Deliouck, M.P., Meresse, S., Delorme, P., Fruchart, J.C., Cecclielli, R., 1990. An easier, reproducible, and mass-production method to study the blood-brain barrier it? vitro. Journal of Neurochemistry 54 (5), 1798-1801], it has been possible to develop a new in vitro BBB system suitable for high throughput screening (HTS). In addition, this new procedure substantially reduces the use of experimental animals and considerably facilitates the process of obtaining a functional in vitro BBB model. The model is ready to use after only 4 days of culture and then shows the typical expression and localization of tight junction proteins. The function of the P-glycoprotein and the transcriptional expression of other efflux transporters such as MRP 1, 4 and 5 have been demonstrated. In addition, the model produces a good in vitrolin vivo correlation for 10 compounds (R-2 = 0.81). Furthermore, studies were undertaken within the European ACuteTox consortium with the objective to assess BBB toxicity and make risk assessments of potentially toxic compounds according to their predicted ability to reach the CNS compartment. These investigations demonstrated that the results produced in the HTS BBB model were similar to the standard co-culture model. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:799 / 811
页数:13
相关论文
共 38 条
[1]  
[Anonymous], GUID DOC US IN VITR
[2]   Contribution of glial cells and pericytes to the mRNA profiles of P-glycoprotein and multidrug resistance-associated proteins in an in vitro model of the blood-brain barrier [J].
Berezowski, V ;
Landry, C ;
Dehouck, MP ;
Cecchelli, R ;
Fenart, L .
BRAIN RESEARCH, 2004, 1018 (01) :1-9
[3]   Transport screening of drug cocktails through an in vitro blood-brain barrier:: Is it a good strategy for increasing the throughput of the discovery pipeline? [J].
Berezowski, V ;
Landry, C ;
Lundquist, S ;
Dehouck, L ;
Cecchelli, R ;
Dehouck, MP ;
Fenart, L .
PHARMACEUTICAL RESEARCH, 2004, 21 (05) :756-760
[4]  
BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97
[5]   Intercommunications between brain capillary endothelial cells and glial cells increase the transcellular permeability of the blood brain barrier during ischaemia [J].
Brillault, J ;
Berezowski, V ;
Cecchelli, R ;
Dehouck, MP .
JOURNAL OF NEUROCHEMISTRY, 2002, 83 (04) :807-817
[6]   In vitro model for evaluating drug transport across the blood-brain barrier [J].
Cecchelli, R ;
Dehouck, B ;
Descamps, L ;
Fenart, L ;
Buée-Scherrer, V ;
Duhem, C ;
Lundquist, S ;
Rentfel, M ;
Torpier, G ;
Dehouck, MP .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 36 (2-3) :165-178
[7]  
Clemedson C, 1996, ATLA-ALTERN LAB ANIM, V24, P273
[8]  
Clemedson C, 2000, ATLA-ALTERN LAB ANIM, V28, P161
[9]  
Clemedson C, 1996, ATLA-ALTERN LAB ANIM, V24, P251
[10]  
Clemedson C, 1998, ATLA-ALTERN LAB ANIM, V26, P93